| From : | Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G> |
| To : | Zaza Avaliani <avalianizaza@yahoo.com>; Amiran Gamkrelidze <a.gamkrelidze@ncdc.ge>; Tengiz Tsertsvadze <tt@aidscenter.ge> |
| Subject : | RE: COVID-19 Clinical management protocols |
| Cc : | Nana Kiria <nana_kiria@yahoo.com>; Irma Khonelidze <i.khonelidze@ncdc.ge> |
| Received On : | 21.03.2020 16:30 |
დიდი მადლობა ბატონო ზაზა!
From: Zaza Avaliani
Sent: Saturday, March 21, 2020 7:35 PM
To: Tamar Gabunia
Cc: Nana Kiria
Subject: COVID-19 Clinical management protocols
ქალბატონო თამარ, ბატონო ამირან, ბატონო თენგიზ,
გიგზავნით ჩვენი ამერიკელი მეგობრების და პარტნიორების მიერ გაზიარებულ გაიდლაინს (ვაშინგტონის საუნივერსიტეტო კლინიკიდან); ვფიქრობთ, საგულისხმო იქნება.
უაღრესი პატივისცემით,
ზაზა ავალიანი
Zaza Avaliani, MD PhD Professor
Director, National Center for Tuberculosis and Lung Diseases
8, Achara str. Tbilisi, 0101 Georgia
Phone (office): (+995 32) 2910252
Phone (cell): (+995 599) 585336
----- Forwarded Message -----
From: Blumberg, Henry M. <hblumbe@emory.edu>
To: Zaza Avaliani <avalianizaza@yahoo.com>; Kempker, Russell <rkempke@emory.edu>; Nestan Tukvadze <marikushane@yahoo.com>
Sent: Saturday, March 21, 2020, 07:25:29 PM GMT+4
Subject: Re: [External] COVID-19 Clinical managment protocols
Zaza:
Thanks for your email. I am attaching treatment guidelines published by the University of Washington located in Seattle in the state of Washington. Seattle is one of the first US cities to be impacted by COVID-19. As noted in the guidelines, there are no proven effective therapies but they outline some possible options.
Regards,
Henry
PS—Emory and Grady are updating their clinical management guidelines which should be ready soon and we can send those to you when available, hopefully soon.
From: Zaza Avaliani <avalianizaza@yahoo.com>
Date: Saturday, March 21, 2020 at 10:22 AM
To: Russell Kempker <rkempke@emory.edu>, Nestan Tukvadze <marikushane@yahoo.com>, "Henry M. Blumberg" <hblumbe@emory.edu>
Subject: Re: [External] COVID-19 Clinical managment protocols
Dear Henry,
Thank you so much for your email!
We try to keep with all important work running but crisis is close and hope we can cope with it.
Wish you, your family and all colleagues in US to stay safe! We follow on daily news and seems it is difficult times for US as in Europe and other parts of the world.
Indeed we will miss gathering for Fogarty Conference but I second you this is the only possible approach now.
We keep in touch and looking forward to see your Clinical protocols, thank you so much for making them available for us.
Stay Safe!
Zaza
Zaza Avaliani, MD PhD Professor
Director, National Center for Tuberculosis and Lung Diseases
8, Achara str. Tbilisi, 0101 Georgia
Phone (office): (+995 32) 2910252
Phone (cell): (+995 599) 585336
On Saturday, March 21, 2020, 03:18:10 AM GMT+4, Blumberg, Henry M. <hblumbe@emory.edu> wrote:
Zaza:
Thanks for your email. Hoping you and Nestani and all our colleagues in Georgia are doing well. The COVID-19 pandemic is starting to surge now in Atlanta and US Georgia. Thanks so much for looking out for Argita! As Russell mentioned below, we are happy to share the Emory/Grady COVID-19 treatment guidelines. There is no proven effective therapy as you know but the guidelines present some options that could be tried to patients who are more ill.
Unfortunately, as Nestani may have discussed with you, it looks like we will need to cancel the planned in-country conference that we were planning to have May 20-22, 2020 in Kazbegi. Hopefully we can reschedule it in the future if the COVID-19 pandemic resolves or subsides. Right now Emory has instituted travel restrictions for any international travel and the US State Department has issued a travel warning (level 4, highest level) for no international travel for Americans. Lets hope in the coming weeks and months things improve globally.
Stay safe!
Regards,
Henry-
From: Russell Kempker <rkempke@emory.edu>
Date: Friday, March 20, 2020 at 3:28 PM
To: Zaza Avaliani <avalianizaza@yahoo.com>, Nestan Tukvadze <marikushane@yahoo.com>, "Henry M. Blumberg" <hblumbe@emory.edu>
Subject: Re: [External] COVID-19 Clinical managment protocols
Dear Zaza, We will definitely share our treatment protocol once it gets updated. We had a call to discuss today and hopefully they will be sending out later tonight, Russell
Russell Kempker, MD, MSc
Associate Professor
Emory University School of Medicine, Division of Infectious Diseases
Office: 404-251-8701
Email: rkempke@emory.edu
From: Zaza Avaliani <avalianizaza@yahoo.com>
Sent: Friday, March 20, 2020 3:23 PM
To: Nestan Tukvadze <marikushane@yahoo.com>; Blumberg, Henry M. <hblumbe@emory.edu>; Kempker, Russell <rkempke@emory.edu>
Subject: Re: [External] COVID-19 Clinical managment protocols
Dear Russell, Henry,
We feel we are in the middle of the war and weapons are catching up slowly.
Thank you so much for sharing the laboratory test protocol! With your permission will share it with NCDC. We will be looking forward to see Emory / Grady treatment protocols, it will help us a lot to develop our own ones.
We will take care of Argita...
Thank you so much and Stay Safe!
Zaza
Zaza Avaliani, MD PhD Professor
Director, National Center for Tuberculosis and Lung Diseases
8, Achara str. Tbilisi, 0101 Georgia
Phone (office): (+995 32) 2910252
Phone (cell): (+995 599) 585336
On Friday, March 20, 2020, 08:26:25 PM GMT+4, Kempker, Russell <rkempke@emory.edu> wrote:
Dear Nestani, Good to talk today.
Dear Zaza, Hope all is well with you and family and everyone is staying safe, socially isolated (as much as HCWs can do) and sane.
Here is a link for the Abbott test our lab is working on implementing. We had a successful first run yesterday and hope to have it validated and up and running with a capacity of ~270 per day if needed: https://www.abbott.com/corpnewsroom/product-and-innovation/abbott-launches-novel-coronavirus-test.html.
We will share our guidance about treatment guidelines for Emory/Grady after it is updated. I am also sharing a great review of this past week's COVID literature put together by our ID Fellows and please feel free to share,
Russell
Abbott has received emergency use authorization (EUA) from the FDA for its molecular test for the identification of SARS-CoV-2, the virus that causes COVID-19.. The company is deploying 150,000 laboratory tests immediately. Tests already have been sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington. |
Russell Kempker, MD, MSc
Associate Professor
Emory University School of Medicine, Division of Infectious Diseases
Office: 404-251-8701
Email: rkempke@emory.edu
From: Nestan Tukvadze <marikushane@yahoo.com>
Sent: Friday, March 20, 2020 12:01 PM
To: Kempker, Russell <rkempke@emory.edu>; Blumberg, Henry M. <hblumbe@emory.edu>
Cc: Zaza Avaliani <avalianizaza@yahoo.com>
Subject: [External] COVID-19 Clinical managment protocols
Dear Henry, Russell,
It was great to talk to you today!
I hope in US and in Georgia all will be fine and we will cope with evolving pandemic in a best possible way.
As I mentioned during the call, we together with Dr. Zaza will be looking forward to your clinical guideline / protocol for COVID-19 clinical management whenever the updated one is available. I took the lesson from you: with limited evidence around there is a very limited treatment possibilities in fact.
Thank you so much for your continuous support!
Nestani
Nestani Tukvadze, MD
Head of Research Unit,
National Center for Tuberculosis and Lung Diseases
50 Maruashvili str 0101 Tbilisi, Georgia
Cell: +995593733334
This e-mail message (including any attachments) is for the sole use of
the intended recipient(s) and may contain confidential and privileged
information. If the reader of this message is not the intended
recipient, you are hereby notified that any dissemination, distribution
or copying of this message (including any attachments) is strictly
prohibited.
If you have received this message in error, please contact
the sender by reply e-mail message and destroy all copies of the
original message (including attachments).